New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
09:02 EDTARWRArrowHead Research to publish data of ARC-520 study
Arrowhead Research announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days after a single injection in animal models. This suggests that Arrowhead's RNAi-based candidate ARC-520 has the potential to treat chronic hepatitis B virus infection in a fundamentally different manner, with the goal of achieving a functional cure. The paper, entitled "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection," by Wooddell et al, was published online ahead of print in the journal Molecular Therapy. In the publication, Arrowhead scientists describe the use of a novel Dynamic PolyConjugate technology to deliver small interfering RNAs designed against the hepatitis B virus.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
10:49 EDTARWRArrowhead strengthened position in RNAi with Novartis deal, says Piper Jaffray
After Arrowhead Research (ARWR) purchased Novartisí (NVS) RNAi R&D portfolio and associated assets for $35M in cash and stock, Piper Jaffray said it believes the deal further consolidates and strengthens Arrowhead's position in the RNAi space. The firm maintains its $12 price target and Overweight rating on Arrowhead shares.
08:01 EDTARWRArrowhead to host conference call
Subscribe for More Information
07:31 EDTARWRArrowhead acquires Novartis' RNAi research and development portfolio
Subscribe for More Information
February 23, 2015
07:33 EDTARWRArrowhead initiates dosing in phase 1 trial of ARC-AAT
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use